Low lymphocyte count a risk factor for infections for people taking HCV therapy
Faldaprevir demonstrates good early response in genotype 1 HIV/HCV co-infection
Simeprevir with interferon effective for HIV/HCV co-infected people with genotype 1 hepatitis C
Daclatasvir works well against hepatitis C either with interferon or in all-oral regimen
Treating HCV genotypes 2 and 3 in HIV/HCV co-infected people
HIV/HCV co-infected people can do well on hepatitis C triple therapy despite contraindications
Fear of future health problems encourage people to start and complete HCV therapy but concern about side-effects is a deterrent
Triple-drug HCV therapy comes with high risk of serious adverse events for people with cirrhosis
French studies report real-world data on use of telaprevir and boceprevir in people with HIV and hepatitis C co-infection
